United States
Print page content Print
Increase text size Decrease text size
Text Size

In this section

What is Palladia?

PALLADIA is a novel FDA approved antineoplastic drug for dogs

  • PALLADIA (toceranib phosphate) belongs to the receptor tyrosine kinase (RTK) inhibitor class of antineoplastic agents1,2
  • PALLADIA is the only antiangiogenic and antiproliferative therapy specifically developed for the treatment of canine cancer2
  • There are several RTK compounds that have been proven to be efficacious in the treatment of some human cancers2
  • PALLADIA is indicated for the treatment of Patnaik grade 2 or 3, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs1

IMPORTANT SAFETY INFORMATION: During clinical studies, the most common adverse events associated with PALLADIA included: diarrhea, anorexia (including decreased appetite), lethargy, neutropenia, emesis, lameness, weight loss, musculoskeletal disorder, and blood in stool/GI bleed/hemorrhagic diarrhea. PALLADIA may cause vascular dysfunction, which can lead to edema and thromboembolism, including pulmonary thromboembolism. Serious and sometime fatal GI complications, including GI perforation, have occurred rarely in dogs treated with PALLADIA. If GI ulceration is suspected stop drug administration and treat appropriately. Children should not come in contact with PALLADIA. In addition, all individuals, including children and pregnant women, should avoid direct contact with broken or partially dissolved PALLADIA tablets or biological waste from dogs treated with PALLADIA. To report a suspected adverse reaction call Zoetis at 1-888-963-8471. See full Prescribing Information

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. Zoetis Inc. All rights reserved. August 2015. PAL-00040

REFERENCES:

1. Package Insert
2. London CA et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003 Jul;9:2755-68.